Unicycive Therapeutics, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Cash, Cash Equivalents, and Marketable Securities

Cash, Cash Equivalents, and Marketable Securities

3 Months Ended

Mar. 31, 2026

Cash, Cash Equivalents, and Marketable Securities [Abstract]

Cash, Cash Equivalents, and Marketable Securities

3. Cash, Cash Equivalents, and Marketable Securities

The following table summarizes the Company’s investments as of March 31, 2026 (in thousands):

	Amortized Cost Basis		Unrealized Gains		Unrealized Losses		Estimated Fair Value

Cash	$	37,371	$	-	$	-	$	37,371
Investments in corporate bonds		17,210		5				17,215
Total cash, cash equivalents and investments in marketable securities	$	54,581	$	5	$	-	$	54,586

The following table summarizes the Company’s investments as of December 31, 2025 (in thousands):

	Amortized Cost Basis		Unrealized Gains		Unrealized Losses			Estimated Fair Value

Cash	$	24,172	$	-	$	-		$	24,172
U.S. Treasury Bills		3,449		-		-			3,449
Money Market		1,577							1,577
Investments in corporate bonds		12,072		-		(1	)		12,071
Total cash, cash equivalents and investments in marketable securities	$	41,270	$	-	$	(1	)	$	41,269

The Company classifies its investments in corporate bonds as available-for-sale. Unrealized gains and losses on these securities are included as a component of comprehensive income (loss). The Company’s investments in corporate bonds as of March 31, 2026 is $17.2 million and as of December 31, 2025 was $12.1 million.

On March 31, 2026, the remaining contractual maturities of all the Company’s available-for-sale investments were less than twelve months. As of March 31, 2026, the Company has not established an allowance for credit losses for any of its available-for-sale securities.